药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2014年
3期
271-273
,共3页
梅丹%倪美鑫%冯平%顾海娟%顾湘
梅丹%倪美鑫%馮平%顧海娟%顧湘
매단%예미흠%풍평%고해연%고상
氨茶碱%血药浓度监测%高效液相色谱法%合理用药
氨茶堿%血藥濃度鑑測%高效液相色譜法%閤理用藥
안다감%혈약농도감측%고효액상색보법%합리용약
Aminophylline%Plasma Concentration Monitoring%HPLC%Rational drug use
目的：分析氨茶碱治疗的肿瘤患者血药浓度监测结果，以期发现临床用药存在的问题及各种因素对肿瘤患者氨茶碱血药浓度的影响。方法：采用5~20μg·mL-1作为氨茶碱血药浓度治疗窗，利用高效液相色谱法测定氨茶碱血药浓度。结果：57.4%的病例氨茶碱血药浓度在5~20μg·mL-1，其中28例临床显示有效，有效率为71.8%；发生中毒反应3例，发生率7.7%。血药浓度<5μg·mL-1的19例中，有效的有6例，占31.6%。>20μg·mL-1的10例中有效3例，其余7例出现多种中毒表现。合并使用西咪替丁、环丙沙星用药，氨茶碱血药浓度升高；合并使用多潘立酮、硝苯地平或特布他林，则氨茶碱血药浓度降低。结论：氨茶碱血药浓度受诸多因素影响，肿瘤患者合并用药时应及时监测氨茶碱的血药浓度，以确保临床疗效，减少毒副反应的发生。
目的：分析氨茶堿治療的腫瘤患者血藥濃度鑑測結果，以期髮現臨床用藥存在的問題及各種因素對腫瘤患者氨茶堿血藥濃度的影響。方法：採用5~20μg·mL-1作為氨茶堿血藥濃度治療窗，利用高效液相色譜法測定氨茶堿血藥濃度。結果：57.4%的病例氨茶堿血藥濃度在5~20μg·mL-1，其中28例臨床顯示有效，有效率為71.8%；髮生中毒反應3例，髮生率7.7%。血藥濃度<5μg·mL-1的19例中，有效的有6例，佔31.6%。>20μg·mL-1的10例中有效3例，其餘7例齣現多種中毒錶現。閤併使用西咪替丁、環丙沙星用藥，氨茶堿血藥濃度升高；閤併使用多潘立酮、硝苯地平或特佈他林，則氨茶堿血藥濃度降低。結論：氨茶堿血藥濃度受諸多因素影響，腫瘤患者閤併用藥時應及時鑑測氨茶堿的血藥濃度，以確保臨床療效，減少毒副反應的髮生。
목적：분석안다감치료적종류환자혈약농도감측결과，이기발현림상용약존재적문제급각충인소대종류환자안다감혈약농도적영향。방법：채용5~20μg·mL-1작위안다감혈약농도치료창，이용고효액상색보법측정안다감혈약농도。결과：57.4%적병례안다감혈약농도재5~20μg·mL-1，기중28례림상현시유효，유효솔위71.8%；발생중독반응3례，발생솔7.7%。혈약농도<5μg·mL-1적19례중，유효적유6례，점31.6%。>20μg·mL-1적10례중유효3례，기여7례출현다충중독표현。합병사용서미체정、배병사성용약，안다감혈약농도승고；합병사용다반립동、초분지평혹특포타림，칙안다감혈약농도강저。결론：안다감혈약농도수제다인소영향，종류환자합병용약시응급시감측안다감적혈약농도，이학보림상료효，감소독부반응적발생。
Objective: To investigate the effect of various factors on plasma concentration of amino-phylline in tumor patients and ensure the safety and utility of its clinical medication. Methods: Therapeu-tic window of aminophylline was set as 5~20 μg·mL-1. Plasma concentration of aminophylline was deter-mined by high performance liquid chromatography (HPLC) and the results were analyzed statistically. Re-sults: Among the 68 sampled cases, 57.4% of the cases were within the effective plasma concentration range of 5 to 20μg·mL-1, of which 28 cases showed therapeutic efficacy, accounting for 71.8% of the 39 cases; The incidence of toxic effect was 7.7%(3 cases). For the 19 cases with plasma concentration under 5μg·mL-1, the effective rate was 31.6%(6 cases). Among the 10 cases with plasma concentration over 20μg· mL-1, 3 cases showed therapeutic efficacy and a variety of toxic manifestations were observed in the other 7 cases. Plasma concentration of aminophylline was increased when it was used in combination with cime-tidine or ciprofloxacin, and was decreased with domperidone, nifedipine or terbutaline. Conclusion: Plasma concentration of aminophylline in tumor patients was affected by various factors. It's necessary to monitor its plasma concentration timely, especially when it is used in combination with other drugs, which is of great significance to reduce its toxic effect and ensure its therapeutic efficacy.
